https://www.selleckchem.com/pr....oducts/ide397-gsk-43
High-dose methotrexate (HD-MTX)-based chemotherapy regimen is the first-line treatment of primary central nervous system lymphoma (PCNSL). At present, doses of MTX in the range of 3.5-8 g/m are frequently used. However, the optimal dose of methotrexate for PCNSL remains controversial. The purpose of this real-world study was to compare the efficacy and toxicity of HD-MTX in patients with untreated PCNSL. Immunocompetent adults with newly diagnosed PCNSL between January 2015 and December 2018 were investigated and followed up
Like
Comment
Share
